Why Is LEGEND BIOTECH CORP ADR (LEGN) Stock Up Today?
By the Top Tier Newswire AI Desk · August 11, 2026 at 9:50 AM ET · reviewed against 7 wire stories
LEGEND BIOTECH CORP ADR (LEGN) is up +7.31% in the latest session. Our newswire has captured 7 stories on LEGN across 6 sources in the last 36 hours, with AI sentiment reading bullish (avg 60/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why LEGN stock is up today
Legend Biotech (LEGN) shares rose 7.31% to $22.17 in early trading on Monday, driven by the company's second-quarter 2026 earnings report. The stock opened with a 1.9% gap up and reached an intraday high of $22.35 before settling near $22.15. The move reflects the company's first quarter of company-wide profitability on both an IFRS and adjusted basis, alongside strong sales of its flagship product, CARVYKTI.
What Happened
Legend Biotech reported second-quarter 2026 results that highlighted continued global growth for CARVYKTI, with revenue rising 51.9% year-over-year to $387.5 million. The company reported non-GAAP earnings per share of $0.16, which missed the expected $0.28 but exceeded the prior year’s $0.03. The report also noted a cash position of $1.1 billion, a result of a recent ADS offering that generated $212 million in net proceeds. Management emphasized the company’s path to sustained profitability in 2026, citing strong product performance and a robust cash position. Additionally, the CEO transition from Ying Huang to Alan Bash as interim CEO was disclosed, though it did not appear to affect the market reaction directly.
What The Data Shows
Intraday volume was 0.4 million shares, or 20% of the 3-month daily average. The stock has traded in a 52-week range of $16.24 to $38.35 and has risen 8.7% over the last 8 sessions. Over the past 30 days, sentiment has improved from 51/100 to 60/100. Recent insider transactions include two sales totaling $171,000, with no insider purchases reported in the last 90 days. The stock is currently unprofitable with a trailing twelve-month EPS of -1.38 and a net margin of -22.0%, but revenue has grown 56.4% year-to-date.
What To Watch
The company has already reported its second-quarter earnings, but investors may continue to monitor coverage breadth as seven stories from six sources have appeared in the last 36 hours. Analysts from HC Wainwright & Co. and RBC Capital have maintained positive outlooks, with updated price targets of $65 and $59, respectively.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
LEGN · today's session (5-min) · +6.00% vs prior close · updated 1:40 PM ETAI sentiment, last 36h · averaged over 7 stories · 60/100 bullish
The headlines behind the move
Story flow · 7 stories on the wire, last 36h · hover or tap a dot for the headline
4h agoYahoo FinanceBULLISH 68Earnings
Legend Biotech Q2 Earnings Call Highlights
Legend Biotech (NASDAQ:LEGN) reported second-quarter 2026 results marked by continued global growth for CARVYKTI and the company’s first quarter of company-wide profitability on both an IFRS and adjusted basis, management said during its earnings call. Interim Chief Executive Officer Alan Bash said
5h agoInvesting.com MarketsNEUTRAL 50General
Why is Legend Biotech stock surging today?
Why is Legend Biotech stock surging today?
6h agoMarketChameleonBULLISH 76Earnings
Legend Biotech Achieves Profitability and Breakthroughs in Cell Therapy with Q2 2026 Results
August 11, 2026
Legend Biotech delivered its first quarterly profit alongside strong CARVYKTI® sales, pipeline breakthroughs, and a robust cash position, positioning the company for sustained growth in cell therapy and oncology.
6h agoThe FlyBULLISH 73Earnings
Legend Biotech reports Q2 EPS 16c vs. 3c last year
6h agoSeeking AlphaBEARISH 42Earnings
Legend Biotech Non-GAAP EPS of $0.16 misses by $0.12, revenue of $387.5M beats by $35.75M
Legend Biotech press release (LEGN): Q2 Non-GAAP EPS of $0.16 misses by $0.12. Revenue of $387.5M (+51.9% Y/Y) beats by $35.75M. Cash Position: Cash and cash equivalents, and time deposits
7h agoStockTitanBULLISH 58Earnings
Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights
CARVYKTI sales rose 50% to about $657M; an ADS offering generated about $212M in net proceeds, and Legend believes it will achieve company-wide profit in 2026.
1d agoSeeking AlphaBULLISH 56Earnings
Legend Biotech Q2 2026 Earnings Preview
Legend Biotech (LEGN) is scheduled to announce Q2 earnings results on Tuesday, August 11th, before market open. The consensus EPS Estimate is $0.28 (+182.4% Y/Y
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →